Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

Published:2017-05-07 Issue:3 Volume:12 Page:277-288
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Serrano César,George Suzanne,Valverde Claudia,Olivares David,García-Valverde Alfonso,Suárez Cristina,Morales-Barrera Rafael,Carles Joan

Funder

SARC Sarcoma SPORE

Instituto de Salud Carlos III (ES)

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s11523-017-0490-9/fulltext.html

Reference105 articles.

1. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Comp Cancer Netw JNCCN. 2010;8(Suppl 2):S1–41.

2. Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Peoc’h M, Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6(8):e20294. doi: 10.1371/journal.pone.0020294 .

3. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11(12):865–78. doi: 10.1038/nrc3143 .

4. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 2010;467(7317):849–53. doi: 10.1038/nature09409 .

5. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10. doi: 10.1126/science.1079666 .

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials;Cell Stress and Chaperones;2024-10

2. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China;European Journal of Cancer;2024-01

3. Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors;Future Oncology;2023-12-05

4. c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights;OncoTargets and Therapy;2023-09

5. LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib;International Journal of Molecular Sciences;2023-04-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3